The myxobacterial metabolite soraphen A inhibits HIV-1 by reducing virus production and altering virion composition

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Fleta Soriano, Eric, 1983-ca
• dc.contributor.author Smutná, Katarína, 1991-ca
• dc.contributor.author Martinez, Javier P.ca
• dc.contributor.author Lorca Oró, Cristinaca
• dc.contributor.author Sadiq, S. Kashifca
• dc.contributor.author Mirambeau, Gillesca
• dc.contributor.author Lopez-Iglesias, Carmenca
• dc.contributor.author Bosch, Martaca
• dc.contributor.author Pol, Albertca
• dc.contributor.author Brönstrup, Markca
• dc.contributor.author Díez Antón, Juana, 1962-ca
• dc.contributor.author Meyerhans, Andreasca
• dc.date.accessioned 2017-09-28T11:22:15Z
• dc.date.issued 2017
• dc.description.abstract Soraphen A is a myxobacterial metabolite that blocks the acetyl-coenzyme A carboxylase of the host and was previously identified as a novel HIV inhibitor. Here, we report that soraphen A acts by reducing virus production and altering the gp120 virion content, impacting entry capacity and infectivity. These effects are partially reversed by addition of palmitic acid, suggesting that inhibition of HIV envelope palmitoylation is one of the mechanisms of antiviral action.
• dc.description.sponsorship The research was funded by the German Centre for Infection Research (DZIF), Spanish Ministry of Economy, Industry and Competitiveness and FEDER BES-2011-048569, Spanish Ministry of Economy, Industry and Competitiveness and FEDER SAF2013-46077-R SAF2016-75505-R, the Spanish Ministry of Economy, Industry and Competitiveness and FEDER BFU2016-80039-R and the Maria de Maetzu Programme for Units of Excellence in R&DMDM-2014-0370
• dc.format.mimetype application/pdfca
• dc.identifier.citation Fleta-Soriano E, Smutná K, Martínez JP, Lorca Oró C, Sadiq SK, Mirambeau G et al. The myxobacterial metabolite soraphen A inhibits HIV-1 by reducing virus production and altering virion composition. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00739-17. DOI: 10.1128/AAC.00739-17
• dc.identifier.doi http://dx.doi.org/10.1128/AAC.00739-17
• dc.identifier.issn 0066-4804
• dc.identifier.uri http://hdl.handle.net/10230/32829
• dc.language.iso eng
• dc.publisher American Society for Microbiologyca
• dc.relation.ispartof Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00739-17
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/BES2011-048569
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2013-46077
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2016-75505-R
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/BFU2016-80039-R
• dc.rights © American Society for Microbiology
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.other Virus
• dc.subject.other Medicaments antivírics
• dc.subject.other VIH (Virus)
• dc.title The myxobacterial metabolite soraphen A inhibits HIV-1 by reducing virus production and altering virion compositionca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion